Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04305041
Brief Title: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

First Submitted : March 9, 2020
First Submitted that Met QC Criteria : March 9, 2020
First Posted : March 12, 2020

Last Update Submitted that Met QC Criteria : September 23, 2021
Last Update Posted : September 24, 2021 (Estimate)